Challenges and opportunities in the delivery of cancer therapeutics

Therapeutic Delivery

Volumn 2, Issue 1, 2011, Pages 107-121

  Richard, Joel ^a  

^a IPSEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; BEVACIZUMAB; CD34 ANTIBODY; CELL PENETRATING PEPTIDE; CYCLOSPORIN A; DOXORUBICIN; ELACRIDAR; ETOPOSIDE; EXCIPIENT; GLYCOPROTEIN P; LIPID; MEGESTROL ACETATE; MONOCLONAL ANTIBODY; NANOCARRIER; OLIGONUCLEOTIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITONAVIR; SAQUINAVIR; SMALL INTERFERING RNA;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; HUMAN; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; SUSTAINED DRUG RELEASE; TARGET CELL;

EID: 79954465611     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.89     Document Type: Review

References (44)

1. McLeod HL, Evans WE. Oral chemotherapy: the promise and the pitfalls. Clin. Cancer Res. 5, 2669-2671 (1999).
2. Hande K, Messenger M, Wagner J, et al. Inter-and intrapatient variability in etoposide kinetics with oral and intravenous drug administration. Clin. Cancer Res. 5, 2742-2747 (1999). (Pubitemid 29493947)
3. Wu Y, Loper A, Landis E, et al. The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int. J. Pharm. 285, 135-146 (2004). (Pubitemid 39361543)
4. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature Rev. Drug Disc. 6, 231-248 (2007). (Pubitemid 46344627)
5. Hauss DJ. Oral lipid-based formulations. Adv. Drug Delivery Rev. 59, 667-676 (2007). (Pubitemid 47285409)
6. O'Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility-the potential impact of lipid-based formulations. Adv. Drug Delivery Rev. 60, 617-624 (2008).
7. Backensfeld T, Schulze J, Lienau P, et al. Modern formulations strategies to overcome physico-chemical and biological barriers of intestinal absorption. Presented at: Optimizing Drug Formulation Conference. London, UK, 12-13 February 2007.
8. Meerum Terwogt JM, Malingré MM, Beijnen JH, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin. Cancer Res. 5, 3379-3384 (1999).
9. Bardelmeijer HA, Beijnen JH, Brouwer KR, et al. Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6, 4416-4421 (2000).
10. Varma MVS, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur. J. Pharm. Sci. 25, 445-453 (2005). (Pubitemid 40853872)
11. Malkov D, Angelo R, Wang HZ, et al. Oral delivery of insulin with the Eligen® technology: mechanistic studies. Curr. Drug Deliv. 2(2), 191-197 (2005). (Pubitemid 40488628)
12. Soltero R, Nnochiri E. The oral delivery of protein and peptide drugs. A variety of strategies can be used to overcome the barriers to protein/peptide drug delivery by the oral route. Innov. Pharm. Technol. 106-110 (2007).
13. Mrsny RJ. A novel strategy for oral protein delivery. Presented at: Controlled Release Conference. London, UK, 13-14 February 2006.
14. Baumgartner S, Kristl J, Vrecer F, et al. Optimisation of floating matrix tablets and evaluation of gastric residence time. Int. J. Pharm. 195, 125-135 (2000). (Pubitemid 30089497)
15. Whitehead L, Fell JT, Collett JH, et al. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J. Control. Release 55, 3-12 (1998). (Pubitemid 28477559)
16. Bosch HW. Product opportunities with NanoCrystal® technology. Presented at: Drug Delivery Global Summit. London, UK, 21-22 September 2005.
17. Liu Y, Huang L, Liu F. Paclitaxel NanoCrystal® for overcoming multidrug resistance in cancer. Mol. Pharm. 7(3), 863-869 (2010).
18. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631-651 (2002). (Pubitemid 35247520)
19. Matsumura Y, Maeda. H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46(12), 6387-6392 (1986). (Pubitemid 17221789)
20. Kreuter J, Alyautdin RN, Kharkevich DA, et al. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674(1), 171-174 (1995).
21. Ringe K, Walz CM, Sabel BA. Nanoparticle drug delivery to the brain. In: Encyclopedia of Nanoscience & Nanotechnology. Nalwa HS (Ed.). American Scientific Publishers, CA, USA (2004).
22. Andrieux K, Couvreur P. Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(5), 463-474 (2009).
23. Calvo P, Gouritin B, Chacun H, et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm. Res. 18(8), 1157-1166 (2001). (Pubitemid 32900402)
24. Rapaport M, Lorberbum-Galski H. TAT-based drug delivery system-new directions in protein delivery for new hopes? Expert Opin. Drug Deliv. 6(5), 453-463 (2009).
25. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active targeting of nanocarriers for anticancer drug delivery. J. Control. Release DOI: 10.1016/j. jconrel.2010.08.27 (2011) (Epub ahead of print).
26. Danhier F. Targeting of tumor endothelium by RGD-grafted PLGA nanoparticles loaded with paclitaxel. J. Control. Release 140, 166-173 (2009).
27. Suzuki R, Namai E, Oda Y, et al. Effective antitumor activity of oxaliplatin encapsulated in transferrin-PEG-liposomes. Int. J. Pharm. 346, 143-150 (2008). (Pubitemid 350101994)
28. Daniels TR, Delgado T, Helguera G, et al. The transferrin receptor part II: targeted delivery of therapeutic agents against cancer cells. Clin. Immunol. 121, 159-176 (2006). (Pubitemid 44572972)
29. Henderson IC, Bhatia V. Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy. Expert Rev. Anticancer Ther. 7(7), 919-943 (2007). (Pubitemid 47180894)
30. De Rosa G, La Rotonda MI. Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties. Molecules 14, 2801-2823 (2009).
31. Toub N, Bertrand JR, Tamaddon A, et al. Efficacy of siRNA nanocapsules targeted against the EWF-Flil oncogene in Ewing sarcoma. Pharm. Res. 23 (5), 892-900 (2006). (Pubitemid 43781397)
32. Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
33. Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J. Cell Sci. 123 (8), 1183-1189 (2010).
34. Hassan Z, Ljungman P, Bolme P, et al. Pharmacokinetics of liposomal busulphan in man. Bone marrow transplant. 27, 479-485 (2001). (Pubitemid 32266497)
35. Meerum Terwogt JM, Groenewegen G, Pluim D, et al. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother. Pharmacol. 49 (3), 201-210 (2002). (Pubitemid 34185593)
36. Lundström E, Rencken R, van Wyk JH, et al. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer. Clin. Drug Investig. 29(12), 757-765 (2009).
37. Siepman J, Faisant N, Akiki J, et al. Effect of size of biodegradable microparticles on drug release: experiment and theory. J. Control. Release 96, 123-134 ( 2004). (Pubitemid 38438495)
38. Brown L. Subcutaneous injectable high concentration monoclonal antibody suspensions. Presented at: GTC Bio Modern Drug Discovery and Development Summit-Drug Delivery Technology. PA, USA, 4-6 December 2006.
39. Crawford J. Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. Pharmacotherapy 23(2), 15S-19S (2003). (Pubitemid 36904014)
40. Kelly JY, DeSimone JM. Shape-specific, monodisperse, nano-molding of protein particles. J. Am. Chem. Soc. 130, 5438-5439 (2008). (Pubitemid 351612948)
41. Gratton SEA, Napier ME, Ropp PA, et al. Microfabricated particles for engineered drug therapies: elucidation into the mechanisms of cellular internalization of PRINT® particles. Pharm. Res. 25, 2845-2852 (2008).
42. Béduneau A, Saulnier P, Hindre F, et al. Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab fragments. Biomaterials 28 (33), 4978-4990 (2007). (Pubitemid 47371148)
43. Huh MS, Lee SY, Park S, et al. Tumor-homing glycol chitosan/ polyethyleneimine nanoparticles for the systemic delivery of siRNA in tumor-bearing mice. J. Control. Rel. 144, 134-143 (2010).
44. Trinity Biosystems, Inc. US0148401 (2009).